1.Wei Z#, Wang S#, Xu Y, Wang W, Soares F, Ahmed M, Su P, Wang T, Orouji E, Xu X, Zeng Y, Chen S, Liu X, Jia T, Liu Z, Du L, Wang Y, Chen SY, Wang C, He HH*,Guo H*. MYC reshapes CTCF-mediated chromatin architecture in prostate cancer.Nature Communications2023, Mar 30;14(1):1787.
2.Guo H#, Wu Y#, Nouri M, Sandor Spisak S, Russo JW, Sowalsky AG, Pomerantz MM, Wei Z, Korthauer K, Seo JH, Wang L, Arai S, Freedman ML, He HH*, Chen S*, Balk SP*. Androgen receptor and MYC equilibration centralizes on developmental super-enhancer.Nature Communications2021, Dec 15; 7308 (2021).
3.Loe AKH#, Francis R#, Seo J, Du L, Wang Y, Kim JE, Hakim SW, Kim JE, He HH,Guo H*,Kim TH*: Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy.J Exp Med2021, Jun 7;218(6):e20200219.
4.Francis R#,Guo H#, Streutker C, Ahmed M, Yung T, Dirks P, He HH*, Kim T-H*: Gastrointestinal transcription factors drive lineage-specific developmental programs in organ specification and cancer.Science Advances2019, Dec 11.
5.Guo H#*, Ci X#, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y*, He HH*. ONECUT2 is a Driver of Neuroendocrine Prostate Cancer.Nature Communications2019, 10(1):278.
6.Wei Z,Guo H*, Qin J, Lu S, Liu Q, Zhang X, Zou Y, Gong Y, Shao C*. Pan-senescence transcriptome analysis identified RRAD as a marker and negative regulator of cellular senescence.Free Radical Biology and Medicine2019, 130:267-277.
7.Guo H#, Ahmed M#, Zhang F, Yao CQ, Li S, Liang Y, Hua J, Soares F, Sun Y, Langstein J,Li Y, Poon C, Bailey SD, Desai K, Fei T, Li Q, Sendorek DH, Fraser M, Prensner JR, Pugh TJ, Pomerantz M, Bristow RG, Lupien M, Feng FY, Boutros PC, Freedman ML, Walsh MJ, He HH.Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer.Nature genetics2016, 48(10):1142-50
8.Guo H#, Ahmed M#, Hua J, Soares F, He HH. Crucial role of noncoding RNA in driving prostate cancer development and progression.Epigenomics2017, 9(1):1-3.(Editorial)
9.Guo H, Liu Z, Xu B, Hu H, Wei Z, Liu Q, Zhang X, Ding X, Wang Y, Zhao M,Gong Y, Shao C. Chemokine receptor CXCR2 is transactivated by p53 and induces p38-mediated cellular senescence in response to DNA damage.Aging cell2013, 12(6):1110-1121.
10.Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J,Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, Lapuk A, Chua MLK, Heisler LE, Foucal A, Fox NS, Fraser M, Bhandari V, Shiah YJ, Guan J, Li J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Liu S, Feng F, Wu X, Shao YW, Komor MA, Sahinalp C, Collins C, Hoogstrate Y, de Jong M, Fijneman RJA, Fei T, Jenster G, van der Kwast T, Bristow RG, Boutros PC, He HH. Widespread and Functional RNA Circularization in Localized Prostate Cancer.Cell. 2019 Feb 7;176(4):831-843.e22.
11.Hua J, Ahmed M,Guo H, Zhang Y, Chen S, Soares F, Lu J, Zhou S, Wang M, Li H, Larson N, McDonnell S, Patel P, Liang Y, Yao CQ, Kwast T, Lupien M, Feng F, Zoubeidi A, Tsao M, Thibodeau SN, Boutros P, He H#. Risk SNPs mediated promoter-enhancer switching promotes prostate cancer development and progression through lncRNA PCAT19.Cell. 2018 Jul 26;174(3):564-575.
